Table 3.
Prevalence of CKD in India
| Author [ref.], year | Assessment of Kidney Function | Prevalence of CKD | |||
|---|---|---|---|---|---|
| Anand et al. [17], 2015 | Spot quantitative urine protein and eGFR (CKD-EPI) | Overall: 7.5% (crude), 8.7% after age standardization | Age and Gender specific prevalence: | ||
| Chennai: | |||||
| Male: 6.6% Female: 6.5% (crude) | |||||
| Male: 7.5% Female: 7.7% (age standardized) | |||||
| Age in years | Male | Female | |||
| 20–44 | 3.5% | 4.6% | |||
| 45–64 | 10.7% | 10.5% | |||
| ≥65 | 21.6% | 16.7% | |||
| Delhi: | |||||
| Male: 8.1% Female: 9.4% (crude) | |||||
| Male: 9.0% Female: 10.8% (age standardized) | |||||
| Age in years | Male | Female | |||
| 20–44 | 5.1% | 6.6% | |||
| 45–64 | 9.5% | 12.0% | |||
| ≥65 | 29.4% | 28.9% | |||
| Anupama et al. [18], 2014 | Spot quantitative urine protein, creatinine clearance and eGFR (CG/BSA & MDRD) | Overall: 6.3% (MDRD), 16.69% (CG/BSA) | Age specific prevalence: | ||
| Age in Years | Prevalence | ||||
| 18–19 | 0.8% | ||||
| 20–29 | 2.4% | ||||
| 30–39 | 3.8% | ||||
| 40–49 | 6.4% | ||||
| 50–59 | 7.5% | ||||
| 60–69 | 16.7% | ||||
| ≥70 | 21% | ||||
| Gender specific prevalence: | |||||
| Male: 8.1% Female: 4.8% (MDRD) | |||||
| Mahapatra et al. [19], 2016 | Spot quantitative urine protein and eGFR (MDRD) | Overall: 27.7% | Age specific prevalence: Not Mentioned |
||
| Gender specific prevalence: Not Mentioned | |||||
| Singh et al. [20], 2009 | Spot quantitative urine protein and eGFR (MDRD, CG/BSA) | Overall: 13.3% (CG/BSA), 4.2% (MDRD) | Age specific prevalence: Not Mentioned |
||
| Gender specific prevalence: Male: 11.1% Female: 16.6% (CG/BSA) | |||||
| Male: 2.7% Female: 6.3% (MDRD) | |||||
| Singh et al. [21], 2013 | Spot quantitative urine protein and eGFR (MDRD) | Overall: 17.2% (MDRD), 16.4% (CKD-EPI) | Age specific prevalence: Not Mentioned |
||
| Gender specific prevalence: Male: 19% Female: 14.9% (MDRD) | |||||
| Trivedi et al. [22], 2016 | Spot quantitative urine protein and eGFR (MDRD) | Overall: 20.93% | Age specific prevalence: | ||
| Age in Years | Prevalence | ||||
| 18–30 | 18.53% | ||||
| 31–40 | 13.74% | ||||
| 41–50 | 20.52% | ||||
| 51–60 | 20.93% | ||||
| 61–70 | 26.77% | ||||
| > 70 | 36.36% | ||||
| Gender specific prevalence: Male: 21% Female: 20.8% | |||||
| Age in Years | Prevalence | ||||
| Male | Female | ||||
| 18–30 | 18.5% | 18.58% | |||
| 31–40 | 11.63% | 16% | |||
| 41–50 | 20.06% | 21.13% | |||
| 51–60 | 22.83% | 17.62% | |||
| 61–70 | 25.33% | 30% | |||
| > 70% | 31.48 | 58.33% | |||
| Varma et al. [23], 2010 | Spot quantitative urine protein and eGFR (CKD-EPI & MDRD) | Overall: 15% (MDRD), 13.1% (CKD-EPI) | Age specific prevalence: Not Mentioned |
||
| Gender specific prevalence: Male: 12.62% Female: 14.13% (CKD-EPI) | |||||
| Male: 13.04% Female: 19.13% (MDRD) | |||||
| Varma et al. [24], 2011 | Spot quantitative urine protein and eGFR (CKD-EPI & MDRD) | Overall: 9.54% | Age specific prevalence: Not Mentioned |
||
| Gender specific prevalence: Not Mentioned | |||||